新出现医疗健康报道时间 2026-10-09 04:34

argenx正在接受证券法违规行为的调查

argenx SE暂停了其Phase 3 UNITY研究，因其被认为无成效，导致其股价下跌10%。SueWallSt通知投资者有关潜在证券法违规行为的调查正在进行。

为什么重要. argenx股东因股价下跌而遭受损失的，可能有资格通过调查获得赔偿。

证据

PPR Newswire news releases公司披露2026-10-09 04:34
argenx said it would discontinue the study.
查看来源
PPR Newswire news releases公司披露2026-10-09 04:34
Shares fell approximately $96.73 per share, or about 10.42% in pre-market trading on October 8, 2026
查看来源
PPR Newswire news releases公司披露2026-10-09 04:34
When the Company disclosed that the study would be discontinued for futility, the stock price declined sharply.
查看来源
PPR Newswire news releases公司披露2026-10-09 04:34
NEW YORK, Oct. 8, 2026 /PRNewswire/ -- argenx SE (NASDAQ: ARGX) stock dropped more than 10% in pre-market trading on October 8, 2026, when the Company halted its Phase 3 UNITY study of subcutaneous Vyvgart in Sjögren's disease for futility. If you bought ARGX and are now holding…
查看来源
PPR Newswire news releases公司披露2026-10-09 04:34
The same morning, argenx also reported positive Phase 2 results for FB102 in celiac disease. ARGX shares fell anyway. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of argenx shareholders who suffered losses in the decl…
查看来源